Jeff Thomis Appointed Chairman of the Board of Idis

Idis, a leading specialist in the creation of managed access programmes for medicines for healthcare professionals and their patients with unmet medical needs, today named Jeff Thomis as the Company’s Chairman.

“I am delighted to be appointed Chairman of Idis. Buy Benicar (Olmesartan) pills online without prescription As specialists in the field, Idis is strongly placed to deliver highly effective solutions to our customers who include pharmaceutical and biotech companies, healthcare professionals and patients”

The appointment is effective immediately. In his new role, Jeff will work with the Board and the leadership team in delivering the company’s future growth plans and meeting its goal of becoming the global authority in access to medicines worldwide.
Jeff spent 15 years at Quintiles, the global clinical research organisation, including as President of Global Clinical Development Services and Chairman of the American Management Board. Buy Benicar Hct (Olmesartan - Hydrochlorothiazide) tabs online without prescription He brings a wealth of pharma and clinical research strategic leadership experience at board level. His expertise lies in helping to grow international businesses in a rapidly changing healthcare environment.
“I am delighted to be appointed Chairman of Idis. As specialists in the field, Idis is strongly placed to deliver highly effective solutions to our customers who include pharmaceutical and biotech companies, healthcare professionals and patients,” said Jeff Thomis. Buy Ticlid (Ticlopidine) without prescription Commenting on his new role, Thomis added, “I look forward to working with the Board at Idis to ensure we drive the growth of the organisation whilst maintaining our patient focused approach to developing and delivering the best managed access programmes.”

- ENDS -

About Idis
Idis has 25 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Buy Vitamins online Since 1987, Idis has developed and managed access to thousands of medicines from every therapeutic category, impacting the lives of hundreds of thousands of patients in countries around the world.
Idis leverages decades of experience, regulatory insight, and a thorough understanding of local and global requirements to create access to medicines at every stage of a product’s lifecycle from pre-approval to market exit, and in times of unexpected production shortages.
The company’s European headquarters are located in Weybridge, United Kingdom, and North American headquarters are located in Princeton, NJ.
About Jeff Thomis
Jeff spent 15 years at Quintiles, the global clinical research organisation during which time he was President of the European Clinical Development Services and then President of Global Clinical Development Services. Medical Questions and Answers Most recently he was Chairman of the American Management Board, reporting to Dennis Gillings, Chairman and CEO of Quintiles. Jeff has grown businesses across Europe, International and US markets in a number of roles, establishing Quintiles Clinical Development Services as the leader in the field of Global Clinical Research Organisations.
In his early career, Jeff spent 20 years with Bristol Myers Squibb, playing a major part in the development and registration (NDA, sNDA) of eight commercially successful cardiovascular and infectious disease products. He also has a significant depth of knowledge within the cardiovascular therapy area; he has also managed a large patient access programme with the HIV treatment didanosine (Videx) and served on WHO Committee on access to HIV drugs.
Jeff qualified as a pharmacist from University of Leuven, Belgium and three years later achieved his Ph.D. in Pharmaceutical Sciences, again from the University of Leuven.

Catalent Pharma Solutions, Inc. Extends Exchange Offer

Catalent Pharma Solutions, Inc. (“Catalent”) announced today that it has extended its offer to exchange up to $350,000,000 aggregate principal amount of its 7.875% Senior Notes due 2018 and the guarantees thereof, which have been registered under the Securities Act of 1933, as amended, for any and all of its outstanding 7.875% Senior Notes due 2018 and the guarantees thereof (the “Notes”), respectively, to 5:00 p.m., New York City time, on Monday, July 29, 2013, unless further extended. Buy Valtrex (Valacyclovir) pills online without prescription
The terms and conditions of the exchange offers are set forth in the prospectus dated June 26, 2013.
The exchange offers had been scheduled to expire at 11:59 p.m., New York City time, on Wednesday, July 24, 2013. As of 11:59 p.m., New York City time, on July 24, 2013, Catalent had been advised that $346.9 million in aggregate principal amount, or 99%, of outstanding unregistered Notes, had been validly tendered to the exchange agent by the holders thereof. Buy Uroxatral (Alfuzosin) tabs online without prescription
The exchange agent for the offer is The Bank of New York Mellon, 111 Sanders Creek Parkway, East Syracuse, New York 13057, Attention: Dacia Brown-Jones, Tel: 315-414-3349.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction where such an offering or sale would be unlawful.
Forward Looking Statements
This press release contains both historical and forward-looking statements. Buy Precose (Acarbose) without prescription All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate”, “intend”, “estimate”, “plan”, “project”, “foresee”, “likely”, “may”, “will”, “would” or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. Vertex Enters Agreement with Bristol-Myers Squibb If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent’s expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; and our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission. Buy Vitamins online All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent does not undertake to update any forward-looking statements as a result of new information or future events or developments unless required by law.
About Catalent Pharma Solutions
All Best Rx : Buy drugs online FDA Approved Rx : Online Pharmacy Drugs Rx Guide : Buy drugs online Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J.